Publication date: Jun 23, 2023
The circulating flu viruses merging with the ongoing COVID-19 pandemic raises a more severe threat that promotes the infectivity of SARS-CoV-2 associated with higher mortality rates. Here, we conjugated recombinant receptor binding domain (RBD) of SARS-CoV-2 spike protein onto inactivated influenza A virus (Flu) to develop a SARS-CoV-2 virus-like particle (VLP) vaccine with two-hit protection. This double-hit vaccine (Flu-RBD) not only induced protective immunities against SARS-CoV-2 but also remained functional as a flu vaccine. The Flu core improved the retention and distribution of Flu-RBD vaccine in the draining lymph nodes, with enhanced immunogenicity. In a hamster model of live SARS-CoV-2 infection, two doses of Flu-RBD efficiently protected animals against viral infection. Furthermore, Flu-RBD VLP elicited a strong neutralization activity against both SARS-CoV-2 Delta pseudovirus and wild-type influenza A H1N1 inactivated virus in mice. Overall, the Flu-RBD VLP vaccine is a promising candidate for combating COVID-19, influenza A, and coinfection.
Open Access PDF
| Concepts | Keywords |
|---|---|
| Immunities | Based |
| Influenza | Conjugated |
| Live | Cov |
| Mice | Covid |
| Pseudovirus | Double |
| Flu | |
| Hit | |
| Inactivated | |
| Infection | |
| Influenza | |
| Rbd | |
| Sars | |
| Vaccine | |
| Virus | |
| Vlp |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | influenza |
| disease | VO | vaccine |
| drug | DRUGBANK | Influenza A virus |
| disease | VO | Viruses |
| disease | MESH | COVID-19 pandemic |
| disease | IDO | infectivity |
| pathway | REACTOME | SARS-CoV-2 Infection |
| disease | MESH | viral infection |
| pathway | KEGG | Influenza A |
| disease | MESH | coinfection |